CTXR - Citius Pharma Company Balance Sheet Assets

This daily price chart for Citius Pharmaceuticals (CTXR) on the GURU.Markets platform reflects total assets at 134.94. Citius Pharmaceuticals is expanding its presence in the hospital sector through the supply of effective catheter solutions. The business remains independent of economic cycles, although it is sensitive to the cost of borrowed capital. Profit growth relies on the launch of Mino-Lok and the potential launch of the antineoplastic Lymphir.

CTXR: Citius Pharmaceuticals Aggregate Company Assets 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for citiuspharma.com (CTXR)

- price and consensus price forecast:

Price Performance Chart Citius Pharmaceuticals, Inc.|CTXR - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Citius Pharmaceuticals, Inc.|CTXR - Enterprise Value

- book capitalization data:

Net Asset Value per Share Citius Pharmaceuticals|CTXR - Company Book Value|Capitalization to Book Value Ratio citiuspharma.com|CTXR - Company Total Assets

- debt and liquidity data:

Debt to Capital Citius Pharmaceuticals|CTXR - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Citius Pharmaceuticals, Inc.|CTXR - Company Aggregate Debts|Debts to Book Capitalization Citius Pharmaceuticals, Inc.|CTXR - Company Long-Term Debt|Company Short-Term Debt Citius Pharmaceuticals

Fundamental valuation:Citius Pharma, CTXR

Finished products of Citius Pharmaceuticals Inc.

The commercialization of Mino-Lok and oncology drugs directly impacts total assets, reflecting the resource base for scaling developments at Citius Pharmaceuticals (CTXR). This indicator, reverse-calculated via ROA, integrates equity and liabilities into daily price action, allowing investors to track the company's financial stability between reports and timely identify risks of a deep capital drawdown.

Main competitors